MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia, a direct comparison assessing the efficacy of low-THC to 100 per cent CBD products when treating severe intractable epilepsy.
Read more :
